Eindhoven Startup Raises €53 Million to Combat Migraines with Innovative Implant

2025-05-27 bio

Eindhoven, Tuesday, 27 May 2025.
Salvia BioElectronics has secured €53 million to advance neuromodulation therapy using an ultra-thin implant aimed at reducing migraine attacks, representing a crucial step for new treatment options.

Introduction to Salvia BioElectronics and Its Funding Achievement

Salvia BioElectronics, an Eindhoven-based clinical-stage medical device company, has raised €53 million in a Series B funding round to support the development of its innovative neuromodulation therapy aimed at chronic migraine treatment. The round was spearheaded by Innovation Industries and saw significant participation from Invest-NL, the EIC Fund, and other returning investors. The funding is intended to advance clinical trials and the commercial launch of MySalvia Therapy, a promising solution designed to alleviate the frequency and intensity of migraine attacks [1][2][3].

Exploring the Technology Behind MySalvia Therapy

The therapy leverages an ultra-thin implant that targets specific nerves associated with migraine symptoms. MySalvia Therapy allows users to initiate targeted electrical stimulation directly, utilizing an external device to administer treatment as needed. This approach offers a minimally invasive alternative to existing migraine treatments, which are often inadequate in providing permanent relief. Initial clinical trials indicate a potential reduction in both the frequency and intensity of attacks, and ongoing studies aim to further substantiate these promising early results [1][4][5].

Understanding the Impact of Migraines and Market Need

Migraine is a debilitating neurological condition that affects millions globally, contributing to an annual economic burden of approximately €96.6 billion in lost productivity and medical costs within the European Union and the United States. The inadequacy of current therapies often leads to high dropout rates among sufferers. Thus, the successful development of MySalvia Therapy could significantly improve patient quality of life and reduce socioeconomic costs associated with migraine [1][2][5].

The Role of Dutch Investment in Healthtech Innovation

Despite a challenging investment climate exacerbated by geopolitical tensions and competitive pressures, entities like Invest-NL continue to support innovative healthtech ventures. Invest-NL has strategically focused on projects with high potential impact, like Salvia BioElectronics, adapting its investment strategy to overcome external financial obstacles and promote technological advancements within the Netherlands and beyond [2][6][7].

Bronnen

startup funding neuromodulation therapy